Nanoformulated anti-fungals

Biosergen is developing new formulations based on nano-particles. the new products in this project will be formulations using Biosergen's current development product BSG005. Biosergen is looking for new nano formulations that can have other ways to reach target organs than standard medicines, may have different toxicological profiles or administered in other doses due to accumulation in target organs. The loading of BSG005 into different nano formulations and the stability in nano formulations have been tested. In the last period the focus has been on solubility with test of different nano particles, their loading of BSG005 and the stability. The choice of nano particles is advanced.

More than 1.6 million people are estimated to die of fungal diseases each year, and more than 150 million people have serious fungal diseases. Drugs used in clinics today are becoming resistant or have serious off-target toxic effects, and there is a need for new and better treatments. Biosergen AS is a drug development company that at present has an antifungal compound in clinical phase I. Due to the promising properties of this compound, Biosergen aims to develop additional products based on this lead drug and thereby expand as an innovative Norwegian drug development company with several antifungal applications. The new products to be developed within the project will be new formulations of the Biosergen lead drug. These formulations will be based on the new nanomaterial. In general, Nano formulated drugs can reach other targets than traditionally formulations, they may have different toxicity profile and they may be administrated in lower doses due to accumulation in the sites of infection. The proposed project will have a high level of innovation with several scientific challenges. Both the formulation and the design of the formulations have to be adapted to the lead drug, the specific type of NANO particles and the intended applications. Drug loading, drug stability, bioavailability and pharmacokinetics will be main issues to be resolved with a combination of in vitro and in vivo experiments. Outcome and impact The main objective of the project is to develop two new formulations based on nanotechnology and execute one or two of them all the way through pre-clinical phase. At the end of the project it is intended that Biosergen has one or two new lead drug formulations ready to go into clinical phase I. Due to the level of innovation in this project it is expected that it will increase the competence within formulation of drugs in nanoparticles and how release kinetics from nanoparticles affects fungistatic inhibition/fungicidal efficacy and drug safety in general.